Atherosclerosis

Apolipoprotein-E proves useful for limiting atherosclerotic progression

Published in Gene Therapy Weekly, March 14th, 2002

by Sonia Nichols, senior medical writer - Restoring apolipoprotein production in genetically deficient mice with gene therapy is one way to hinder atherosclerotic progression, according to a U.K. study.

A multicenter investigation conducted in London, England has yielded information suggesting mice that are apolipoprotein E (apoE) deficient (apoE-/-) improve in terms of atherosclerotic progression after their skeletal muscles are made to generate low levels of the protein. Because atherosclerotic changes in the mice mirror those of humans, authors of the new study believe similar therapy could help people with vascular disease.

J. Harris and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-03-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry